Detalhe da pesquisa
1.
Genetic and immune landscape evolution in MMR-deficient colorectal cancer.
J Pathol
; 262(2): 226-239, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37964706
2.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(11): 1181-1195, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37875143
3.
Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer.
Cancer Sci
; 114(3): 1026-1036, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36369901
4.
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
N Engl J Med
; 383(23): 2207-2218, 2020 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33264544
5.
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.
Lancet Oncol
; 23(5): 659-670, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35427471
6.
Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts.
Gastroenterology
; 161(4): 1179-1193, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34197832
7.
Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer.
Clin Trials
; 19(2): 146-157, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35083924
8.
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(5): 665-677, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33812497
9.
Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
BMC Cancer
; 20(1): 91, 2020 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32013902
10.
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy - Authors' reply.
Lancet Oncol
; 23(6): e246, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35654063
11.
Comprehensive Examination of Cholangiocarcinoma Patients Treated with Novel Targeted Therapies after Extended Molecular Profiling on Liquid Biopsies.
Cancers (Basel)
; 16(4)2024 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38398088
12.
Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary.
Cancer Med
; 13(3): e6988, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38404120
13.
Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers.
J Pathol
; 226(1): 84-96, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22015727
14.
The immunomodulatory role of IDO1-Kynurenine-NAD+ pathway in switching cold tumor microenvironment in PDAC.
Front Oncol
; 13: 1142838, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37456260
15.
Functional characterization of the 19q12 amplicon in grade III breast cancers.
Breast Cancer Res
; 14(2): R53, 2012 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22433433
16.
Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.
J Clin Oncol
; 39(33): 3693-3704, 2021 11 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34516759
17.
Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors.
Clin Colorectal Cancer
; 20(4): 342-349, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34696965
18.
DNA amplifications in breast cancer: genotypic-phenotypic correlations.
Future Oncol
; 6(6): 967-84, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20528234
19.
Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?
Genes Chromosomes Cancer
; 48(4): 351-65, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19156836
20.
Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives.
Cancer Treat Rev
; 88: 102030, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32505807